HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jedd D Wolchok Selected Research

Neoplasm Metastasis (Metastasis)

1/2021Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
1/2019Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
10/2018Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
10/2017Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
1/2017Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
11/2016Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
11/2016Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
1/2016Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
5/2015Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
10/2013Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jedd D Wolchok Research Topics

Disease

256Neoplasms (Cancer)
05/2024 - 01/2002
203Melanoma (Melanoma, Malignant)
05/2024 - 01/2002
17Disease Progression
11/2023 - 01/2008
13Neoplasm Metastasis (Metastasis)
01/2021 - 12/2008
11Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2023 - 08/2015
11Experimental Melanoma
11/2021 - 05/2003
10Brain Neoplasms (Brain Tumor)
01/2018 - 09/2003
9Body Weight (Weight, Body)
10/2019 - 08/2010
7Lung Neoplasms (Lung Cancer)
10/2023 - 04/2015
7Inflammation (Inflammations)
01/2021 - 03/2014
7Prostatic Neoplasms (Prostate Cancer)
04/2019 - 10/2003
6Carcinoma (Carcinomatosis)
11/2023 - 05/2010
6COVID-19
10/2022 - 01/2020
6Testicular Neoplasms (Testicular Cancer)
01/2021 - 02/2005
6Colitis
11/2018 - 01/2014
5Uveal melanoma
05/2022 - 04/2011
5Breast Neoplasms (Breast Cancer)
12/2016 - 04/2004
5Vitiligo
07/2014 - 07/2002
4Bites and Stings (Sting)
01/2023 - 05/2017
4Exanthema (Rash)
01/2023 - 05/2012
4Communicable Diseases (Infectious Diseases)
11/2017 - 01/2002
3Renal Cell Carcinoma (Grawitz Tumor)
11/2023 - 01/2018
3Pancreatic Neoplasms (Pancreatic Cancer)
06/2023 - 11/2017
3Infections
05/2017 - 12/2012
3Hypersensitivity (Allergy)
01/2017 - 07/2010
3Fatigue
08/2015 - 05/2012
3Sarcoma (Soft Tissue Sarcoma)
03/2005 - 11/2003
2Cytokine Release Syndrome
12/2023 - 01/2023
2Cardiotoxicity
12/2023 - 10/2018
2Stomach Neoplasms (Stomach Cancer)
11/2023 - 07/2013
2Adenocarcinoma of Lung
10/2023 - 01/2018

Drug/Important Bio-Agent (IBA)

101IpilimumabIBA
05/2024 - 01/2008
55Immune Checkpoint InhibitorsIBA
03/2024 - 07/2013
40NivolumabIBA
05/2024 - 07/2013
38DNA (Deoxyribonucleic Acid)IBA
05/2024 - 01/2002
38AntibodiesIBA
10/2023 - 07/2002
34AntigensIBA
01/2023 - 01/2002
29Monoclonal AntibodiesIBA
10/2019 - 11/2003
26pembrolizumabIBA
11/2023 - 07/2013
22Biomarkers (Surrogate Marker)IBA
01/2021 - 01/2011
21VaccinesIBA
01/2024 - 01/2002
20Proteins (Proteins, Gene)FDA Link
10/2022 - 04/2004
19DNA VaccinesIBA
08/2017 - 01/2002
15Neoplasm Antigens (Tumor Antigens)IBA
01/2023 - 01/2003
15CTLA-4 AntigenIBA
01/2018 - 12/2008
14Peptides (Polypeptides)IBA
10/2022 - 05/2003
14Monophenol Monooxygenase (Tyrosinase)IBA
08/2017 - 04/2003
14AutoantigensIBA
05/2014 - 10/2002
12Programmed Cell Death 1 ReceptorIBA
10/2023 - 07/2013
11B7-H1 AntigenIBA
10/2023 - 11/2016
10Differentiation AntigensIBA
09/2010 - 05/2003
8RNA (Ribonucleic Acid)IBA
10/2023 - 05/2003
8GlucocorticoidsIBA
10/2021 - 04/2009
8InterferonsIBA
01/2021 - 08/2015
7Blocking AntibodiesIBA
01/2021 - 01/2011
7EpitopesIBA
11/2017 - 05/2003
7Temozolomide (Temodar)FDA LinkGeneric
06/2014 - 09/2003
6Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2023 - 04/2013
6EnzymesIBA
01/2023 - 08/2011
6Dacarbazine (DIC)FDA LinkGeneric
04/2015 - 02/2004
5CytokinesIBA
05/2024 - 09/2006
5Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
10/2021 - 04/2009
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2014 - 02/2009
4dabrafenibIBA
12/2023 - 04/2017
4Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2023 - 01/2002
4Cancer VaccinesIBA
01/2022 - 12/2008
4Immunoglobulin G (IgG)IBA
02/2021 - 09/2006
4Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
11/2020 - 08/2011
4LigandsIBA
07/2015 - 05/2006
4Imatinib Mesylate (Gleevec)FDA Link
05/2015 - 05/2011
4HLA-A*02:01 antigenIBA
10/2010 - 11/2007
4Thalidomide (Thalomid)FDA Link
03/2007 - 09/2003
3Immunomodulating AgentsIBA
01/2024 - 02/2015
3cyclic guanosine monophosphate-adenosine monophosphateIBA
01/2023 - 05/2017
3Protein Subunit VaccinesIBA
10/2022 - 07/2010
3Alkylating AgentsIBA
10/2021 - 05/2009
3LipidsIBA
01/2021 - 11/2015
3Transcription Factors (Transcription Factor)IBA
01/2018 - 11/2013
3Interferon-gamma (Interferon, gamma)IBA
01/2017 - 02/2009
3Glycoproteins (Glycoprotein)IBA
11/2016 - 08/2010
3tyrosinase-related protein-1IBA
11/2016 - 05/2006
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
04/2016 - 06/2011
3Complement System Proteins (Complement)IBA
01/2016 - 05/2003
3Interferon Type IIBA
08/2015 - 01/2014
3Interleukin-2 (IL2)IBA
01/2015 - 04/2011
3Therapeutic UsesIBA
05/2014 - 09/2010
3HLA Antigens (Human Leukocyte Antigens)IBA
01/2013 - 11/2007
3Oncogene Proteins (Oncogene Protein)IBA
06/2012 - 07/2010
2eprenetapoptIBA
01/2024 - 01/2022
2trametinibIBA
12/2023 - 10/2023
2tributyl phosphate (TBP)IBA
11/2023 - 11/2017
2Small Cytoplasmic RNAIBA
10/2023 - 01/2022

Therapy/Procedure

130Therapeutics
10/2023 - 01/2002
105Immunotherapy
12/2023 - 01/2002
13Drug Therapy (Chemotherapy)
10/2023 - 06/2005
10Radiotherapy
12/2021 - 06/2010
9Aftercare (After-Treatment)
01/2020 - 11/2003
5Immunomodulation
01/2017 - 03/2013
4Ligation
11/2013 - 05/2006
3Time-to-Treatment
01/2020 - 10/2015